News / Taiwan / cnyes
JingTian Partners with BonoCare to Expand Topical Drug Market in China
Health Technology · Pharmaceuticals: Other · cnyes · 2026-09-11
6917
JingTian has signed an MOU with BonoCare to co-develop topical formulations and accelerate clinical validation and commercialization in the Chinese market.
What Happened
Strategic Partnership: JingTian has entered into a Memorandum of Understanding (MOU) with BonoCare (Beijing) to jointly expand into the Chinese topical drug market. The partnership leverages JingTian’s R&D expertise in novel topical formulations alongside BonoCare’s local regulatory and commercialization capabilities.
Synergy and Goals: The collaboration focuses on developing niche generic drugs and new dosage forms. By utilizing BonoCare’s expertise in high-end inhalation APIs and CDMO services, JingTian aims to shorten the time-to-market for its products while mitigating regulatory and commercial risks.
Financial Performance: JingTian reported strong financial results, with August revenue reaching a record high of NT$1.62 million, driven by licensing fees and robust sales of its core generic drugs. Cumulative revenue for the first eight months of the year surged 5.49 times year-over-year, signaling a successful transition into the commercialization phase.
Future Outlook: With new drug development progressing and generic drug sales growing, JingTian maintains a cautiously optimistic outlook for the next two years. The company intends to continue leveraging strategic partnerships to drive revenue growth and strengthen its market position.